Myositis in Germany: epidemiological insights over 15 years from 2005 to 2019

Bibliographic Details
Title: Myositis in Germany: epidemiological insights over 15 years from 2005 to 2019
Authors: Marc Pawlitzki, Laura Acar, Lars Masanneck, Alice Willison, Liesa Regner-Nelke, Christopher Nelke, Helmut L’hoest, Ursula Marschall, Jens Schmidt, Sven G. Meuth, Tobias Ruck
Source: Neurological Research and Practice, Vol 4, Iss 1, Pp 1-11 (2022)
Publisher Information: BMC, 2022.
Publication Year: 2022
Collection: LCC:Neurosciences. Biological psychiatry. Neuropsychiatry
LCC:Neurology. Diseases of the nervous system
Subject Terms: Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
More Details: Abstract Background The medical care of patients with myositis is a great challenge in clinical practice. This is due to the rarity of these disease, the complexity of diagnosis and management as well as the lack of systematic analyses. Objectives Therefore, the aim of this project was to obtain an overview of the current care of myositis patients in Germany and to evaluate epidemiological trends in recent years. Methods In collaboration with BARMER Insurance, retrospective analysis of outpatient and inpatient data from an average of approximately 8.7 million insured patients between January 2005 and December 2019 was performed using ICD-10 codes for myositis for identification of relevant data. In addition, a comparative analysis was performed between myositis patients and an age-matched comparison group from other populations insured by BARMER. Results 45,800 BARMER-insured individuals received a diagnosis of myositis during the observation period, with a relatively stable prevalence throughout. With regard to comorbidities, a significantly higher rate of cardiovascular disease as well as neoplasm was observed compared to the control group within the BARMER-insured population. In addition, myositis patients suffer more frequently from psychiatric disorders, such as depression and somatoform disorders. However, the ICD-10 catalogue only includes the specific coding of “dermatomyositis” and “polymyositis” and thus does not allow for a sufficient analysis of all idiopathic inflammatory myopathies subtypes. Conclusion The current data provide a comprehensive epidemiological analysis of myositis in Germany, highlighting the multimorbidity of myositis patients. This underlines the need for multidisciplinary management. However, the ICD-10 codes currently still in use do not allow for specific analysis of the subtypes of myositis. The upcoming ICD-11 coding may improve future analyses in this regard.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2524-3489
Relation: https://doaj.org/toc/2524-3489
DOI: 10.1186/s42466-022-00226-4
Access URL: https://doaj.org/article/d35dd452430440b08d7dcc282b5fb5e0
Accession Number: edsdoj.35dd452430440b08d7dcc282b5fb5e0
Database: Directory of Open Access Journals
More Details
ISSN:25243489
DOI:10.1186/s42466-022-00226-4
Published in:Neurological Research and Practice
Language:English